

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Brett Anthony Mitchell
Date of last notice	11 February 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Brett and Michelle Mitchell <Mitchell Spring Family A/C> Trustee Brett and Michelle Mitchell <Lefthanders Super Fund A/C> Trustee Chieftain Securities Pty Ltd Director and 33.3% Shareholder
Date of change	23 December 2019
No. of securities held prior to change	Brett and Michelle Mitchell <Mitchell Spring Family A/C> 20,458,889 Fully Paid Ordinary Shares Brett and Michelle Mitchell <Lefthanders Super Fund A/C> 6,335,005 Fully Paid Ordinary Shares Chieftain Securities Pty Ltd 5,000,000 Unlisted Options exercisable at \$0.15 expiring 30 June 2021
Class	1. Performance Rights 2. Unlisted Options exercisable at \$0.05, \$0.06 and \$0.07 expiring 31 August 2023
Number acquired	1. 10,000,000 2. 4,500,000

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	<ol style="list-style-type: none"> 1. Non-cash – issued as approved by shareholders on 29 November 2019. Estimated total valuation: \$150,500 2. Non-cash – issued as approved by shareholders on 29 November 2019. Estimated valuation: \$0.0152 per option (for \$0.05 options), \$0.0143 per option (for \$0.06 options) and \$0.0135 per option (for \$0.07 options)
No. of securities held after change	<p>Brett and Michelle Mitchell <Mitchell Spring Family A/C> 20,458,889 Fully Paid Ordinary Shares 5,000,000 Performance Rights</p> <p>Brett and Michelle Mitchell <Lefthanders Super Fund A/C> 6,335,005 Fully Paid Ordinary Shares 5,000,000 Performance Rights</p> <p>Chieftain Securities Pty Ltd 5,000,000 Unlisted Options exercisable at \$0.15 expiring 30 June 2021 1,500,000 Unlisted Options exercisable at \$0.05 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.06 expiring 31 August 2023 1,500,000 Unlisted Options exercisable at \$0.07 expiring 31 August 2023</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Performance Rights and Unlisted Options were issued following shareholder approval at the Company's Annual General Meeting held on 29/11/2019. Full details are included in the Notice of Meeting released to shareholders on 29/10/2019.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	MGC Pharmaceuticals Limited
ABN	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Roby Reuven Zomer
Date of last notice	25 February 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Chitta Lu Limited (Director and sole shareholder)
Date of change	23 December 2019
No. of securities held prior to change	Chitta Lu Limited 500,001 Fully Paid Ordinary Shares HSBC Custody Nominees (Australia) Limited 30,000,000 Fully Paid Ordinary Shares
Class	Performance Rights
Number acquired	10,000,000 Performance Rights
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Non-cash – issued as approved by shareholders on 29 November 2019. Estimated total valuation: \$150,500

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

No. of securities held after change	Chitta Lu Limited 500,001 Fully Paid Ordinary Shares 10,000,000 Performance Rights HSBC Custody Nominees (Australia) Limited 30,000,000 Fully Paid Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Performance Rights were issued following shareholder approval at the Company's Annual General Meeting held on 29/11/2019. Full details are included in the in the Notice of Meeting released to shareholders on 29/10/2019.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.